Table. 1.
Animal use table. For all studies, C57BL/6J female mice were treated daily (i.p) until day of euthanasia. EB, Evan’s blue; EM, electron microscopy; FCCP-OCR, carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone-oxygen consumption rate.
| Euthanized Time Point | Animal Numbers | Assessments | Surgical Procedure | Treatment (i.p.) |
|---|---|---|---|---|
| 3d | 5 | FCCP-OCR, copy# | Naïve | Vehicle |
| 3d | 5 | FCCP-OCR, copy# | Naïve | 0.1mg/kg Lasmiditan |
| 3d | 5 | EM | Naïve | Vehicle |
|
| ||||
| 3d | 5 | EM | Naïve | 0.1mg/kg Lasmiditan |
|
| ||||
| 3d | 5 | Protein, copy# | Sham | Vehicle |
|
| ||||
| 3d | 5 | Protein, copy# | SCI | Vehicle |
| 3d | 5 | Protein, copy# | SCI | 0.1mg/kg Lasmiditan |
| 3d | 6 | FCCP-OCR | Sham | Vehicle |
|
| ||||
| 3d | 6 | FCCP-OCR | SCI | Vehicle |
|
| ||||
| 3d | 6 | FCCP-OCR | SCI | 0.1mg/kg Lasmiditan |
|
| ||||
| 3d | 6 | EB | Sham | Vehicle |
| 3d | 6 | EB | SCI | Vehicle |
| 3d | 6 | EB | SCI | 0.1mg/kg Lasmiditan |
| 3d | 2 | EB representative | Sham | Vehicle |
|
| ||||
| 3d | 2 | EB representative | SCI | Vehicle |
|
| ||||
| 3d | 2 | EB representative | SCI | 0.1mg/kg Lasmiditan |
|
| ||||
| 7d | 6 | EB | Sham | Vehicle |
| 7d | 6 | EB | SCI | Vehicle |
| 7d | 6 | EB | SCI | 0.1mg/kg Lasmiditan |
| 7d | 1 | EB representative | Sham | Vehicle |
|
| ||||
| 7d | 1 | EB representative | SCI | Vehicle |
|
| ||||
| 7d | 1 | EB representative | SCI | 0.1mg/kg Lasmiditan |
|
| ||||
| 7d | 6 | Histology | Sham | Vehicle |
|
| ||||
| 7d | 6 | Histology | SCI | Vehicle |
| 7d | 6 | Histology | SCI | 0.1mg/kg Lasmiditan |
|
| ||||
| 7d | 5 | Protein | Sham | Vehicle |
|
| ||||
| 7d | 5 | Protein | SCI | Vehicle |
|
| ||||
| 7d | 5 | Protein | SCI | 0.1mg/kg Lasmiditan |
| 21d | 8 | BMS | Sham | Vehicle |
| 21d | 9 | BMS | SCI | Vehicle |
| 21d | 9 | BMS | SCI | 1.0mg/kg Lasmiditan |
|
| ||||
| 21d | 10 | BMS | SCI | 0.1mg/kg Lasmiditan |
|
| ||||
| 21d | 9 | BMS | SCI | 0.01 mg/kg Lasmiditan |